BRPI0707247A8 - vacina para tumor compreendendo células tumorais alogênicas ou xenogênicas - Google Patents

vacina para tumor compreendendo células tumorais alogênicas ou xenogênicas

Info

Publication number
BRPI0707247A8
BRPI0707247A8 BRPI0707247A BRPI0707247A BRPI0707247A8 BR PI0707247 A8 BRPI0707247 A8 BR PI0707247A8 BR PI0707247 A BRPI0707247 A BR PI0707247A BR PI0707247 A BRPI0707247 A BR PI0707247A BR PI0707247 A8 BRPI0707247 A8 BR PI0707247A8
Authority
BR
Brazil
Prior art keywords
tumor
allogeneic
xenogeneic
cells
cancer
Prior art date
Application number
BRPI0707247A
Other languages
English (en)
Inventor
Stathopoulos Apostolos
Original Assignee
Stathopoulos Apostolos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stathopoulos Apostolos filed Critical Stathopoulos Apostolos
Publication of BRPI0707247A2 publication Critical patent/BRPI0707247A2/pt
Publication of BRPI0707247A8 publication Critical patent/BRPI0707247A8/pt
Publication of BRPI0707247B1 publication Critical patent/BRPI0707247B1/pt
Publication of BRPI0707247B8 publication Critical patent/BRPI0707247B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Semiconductor Lasers (AREA)

Abstract

vacina para tumor compreendendo celulas tumorais alogeneicas ou xenogenéicas a presente invenção provê uma composição para o tratamento de um tumor, compreendendo: (1) células tumorais alogenélcas ou xenogenéicas; e (ii) um excipientefarmaceuticamente aceitável. se dois ou mais indivíduos heterozigóticos têm o mesmo câncer/tumor do mesmo tipo histológico ou de tipo histológico similar, então o transplante das células/tecido de tumor/câncer a partir de um individuo para outro não apenas induzirá a rejeição do tecido/câncer transplantado, mas também aumentará a sensibilização imunológica do sistema imunológico aos peptídeos compartilhados entre os tumores/cânceres e outros tumores possuindo peptídeos similares.
BRPI0707247A 2006-01-26 2007-01-26 vacina para tumor compreendendo células tumorais alogênicas ou xenogênicas BRPI0707247B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0601598.6 2006-01-26
GBGB0601598.6A GB0601598D0 (en) 2006-01-26 2006-01-26 Method
PCT/EP2007/050807 WO2007085648A1 (en) 2006-01-26 2007-01-26 Tumour vaccine comprising allogeneic or xenogeneic tumour cells

Publications (4)

Publication Number Publication Date
BRPI0707247A2 BRPI0707247A2 (pt) 2011-04-26
BRPI0707247A8 true BRPI0707247A8 (pt) 2019-01-22
BRPI0707247B1 BRPI0707247B1 (pt) 2020-09-15
BRPI0707247B8 BRPI0707247B8 (pt) 2021-05-25

Family

ID=36060924

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0707247A BRPI0707247B8 (pt) 2006-01-26 2007-01-26 vacina para tumor compreendendo células tumorais alogênicas ou xenogênicas

Country Status (21)

Country Link
US (1) US8105582B2 (pt)
EP (1) EP1993595B1 (pt)
JP (2) JP5635733B2 (pt)
CN (1) CN101405025B (pt)
AT (1) ATE492287T1 (pt)
AU (1) AU2007209301B9 (pt)
BR (1) BRPI0707247B8 (pt)
CA (1) CA2637690C (pt)
CY (1) CY1111813T1 (pt)
DE (1) DE602007011405D1 (pt)
DK (1) DK1993595T3 (pt)
ES (1) ES2358223T3 (pt)
GB (1) GB0601598D0 (pt)
IL (1) IL192964A (pt)
NO (1) NO338766B1 (pt)
NZ (1) NZ569942A (pt)
PL (1) PL1993595T3 (pt)
PT (1) PT1993595E (pt)
RU (1) RU2456997C2 (pt)
SI (1) SI1993595T1 (pt)
WO (1) WO2007085648A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008299318A1 (en) 2007-09-12 2009-03-19 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Methods of treating tumors in immune-privileged sites
WO2009094387A1 (en) * 2008-01-22 2009-07-30 Ghc Research Development Corporation Compositions and methods for inducing tumor resistance
AU2012257377B2 (en) 2011-05-17 2017-09-07 Hadasit Medical Research Services And Development Ltd. Allogeneic tumor cell vaccination
AU2020395765A1 (en) 2019-12-03 2022-06-16 Neuvogen, Inc. Tumor cell vaccines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6130520A (ja) * 1984-07-19 1986-02-12 Takeda Chem Ind Ltd 抗腫瘍剤
CN1006758B (zh) * 1985-04-01 1990-02-14 哈达·克威斯 抗肿瘤药物组合物的制造方法
JPH04501663A (ja) * 1988-09-23 1992-03-26 ユニバーシティ・オブ・サザン・カリフォルニア 黒色腫用免疫療法ワクチン
GB9827103D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
SI1530628T1 (sl) * 2002-08-16 2011-02-28 Glycotope Gmbh Postopek za proizvodnjo s temperaturo induciranih lizatov tumorskih celic za uporabo kot imunogenske spojine

Also Published As

Publication number Publication date
AU2007209301B2 (en) 2011-01-06
JP2012214499A (ja) 2012-11-08
CA2637690A1 (en) 2007-08-02
CA2637690C (en) 2014-05-06
CN101405025A (zh) 2009-04-08
NO338766B1 (no) 2016-10-17
JP2009524627A (ja) 2009-07-02
BRPI0707247A2 (pt) 2011-04-26
ES2358223T3 (es) 2011-05-06
NZ569942A (en) 2011-08-26
BRPI0707247B8 (pt) 2021-05-25
NO20083519L (no) 2008-09-30
BRPI0707247B1 (pt) 2020-09-15
AU2007209301A1 (en) 2007-08-02
AU2007209301B9 (en) 2011-04-28
CY1111813T1 (el) 2015-10-07
RU2008130457A (ru) 2010-03-10
US8105582B2 (en) 2012-01-31
PT1993595E (pt) 2011-03-23
DE602007011405D1 (de) 2011-02-03
CN101405025B (zh) 2015-12-02
IL192964A0 (en) 2009-02-11
WO2007085648A1 (en) 2007-08-02
JP5635733B2 (ja) 2014-12-03
PL1993595T3 (pl) 2011-07-29
HK1130693A1 (en) 2010-01-08
GB0601598D0 (en) 2006-03-08
SI1993595T1 (sl) 2011-05-31
IL192964A (en) 2011-11-30
ATE492287T1 (de) 2011-01-15
US20100055136A1 (en) 2010-03-04
EP1993595A1 (en) 2008-11-26
DK1993595T3 (da) 2011-03-21
EP1993595B1 (en) 2010-12-22
RU2456997C2 (ru) 2012-07-27

Similar Documents

Publication Publication Date Title
MXPA03000527A (es) Composiciones y metodos para la terapia y diagnostico de cancer ovarico.
ES2373055T3 (es) Péptido antígeno de rechazo de cáncer derivado de glipican-3 (gpc3) para uso en pacientes positivos a la hla-a2 y producto farmacéutico que comprende el antígeno.
EA201590833A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
EA200501206A1 (ru) Производные от сурвивина пептиды и их применение
TN2009000194A1 (en) Novel antiproliferation antibodies
WO2014008206A3 (en) DIAGNOSTIC AND THERAPEUTIC POTENTIAL OF HLA-E MONOSPECIFIC MONOCLONAL IgG ANTIBODIES DIRECTED AGAINST TUMOR CELL SURFACE AND SOLUBLE HLA-E
AR068984A1 (es) Proceso para la obtencion de celulas presentadoras de antigenos activados, utiles en las terapias contra el cancer y enfermedades relacionadas del sistema inmunologico
IL195831A (en) Sparc-derived tumor rejection antigenic peptides and agents inducing immunity against cancers comprising the same
EA200970607A1 (ru) Универсальная вакцина из опухолевых клеток для противораковой терапии и профилактического использования
BRPI0707247A8 (pt) vacina para tumor compreendendo células tumorais alogênicas ou xenogênicas
WO2020018996A3 (en) Delivery of sialidase to cancer cells, immune cells and the tumor microenvironment
MX2009001014A (es) Mediacion de citotoxicidad de celulas que evidencian expresion de cd63 en superficie.
ATE527998T1 (de) Illudin-analoga als krebsmittel
Fujiwara et al. A pilot study of post-operative adjuvant vaccine for advanced gastric cancer Adjuvant cancer vaccine for gastric cancer
BR112014001363A2 (pt) peptídeos mphosph1 e vacinas incluindo os mesmos
BR0015597A (pt) Uso de anticorpos como vacinas
Goldman et al. Long-term outcome after allogeneic hematopoietic cell transplantation (HCT) for CML
Guilarte et al. Laryngeal manifestation of B-cell non-Hodgkin lymphoma
EP2277918A3 (en) Mhc class I and II peptide antigens derived from tumour antigen 5t4
ATE259655T1 (de) Aus ganzen zellen bestehender krebs-impfstoff, enthaltend ko-kultivierte maligne und nicht- maligne zellen
YANG et al. Recent advances on the treatment of hepatocellular carcinoma with portal vein tumor thrombus
Wong Characterization of the role of patient-derived exosomes in cancer and cancer stemness properties in hepatocellular carcinoma (HCC)
XU et al. The application and perspectives of organoids in tumor research
ZHANG et al. Advance on the research and clinical treatment of gastrointestinal stromal tumors
Viola et al. Merkel cell carcinoma

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 3A, 4A E 5A ANUIDADES.

B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: PARA QUE SEJA ACEITA PETICAO 020120060024 DE 29/06/2012, SOLICITAMOS PROCURACAO, COM PODERES PARA O MESMO, CONFORME ART. 216, PARAGRAFO 2O DA LPI 9.279.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B08E Application fees: payment of additional fee required [chapter 8.5 patent gazette]

Free format text: COMPLEMENTAR A RETRIBUICAO DA(S) 6A. ANUIDADE(S), DE ACORDO COM TABELA VIGENTE, REFERENTE A(S) GUIA(S) DE RECOLHIMENTO 22120548115-4.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE (COMPLEMENTACAO).

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2386 DE 27/09/2016.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/01/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2864 DE 25-11-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.